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Abstract. The aim of the present study was to investigate brain 
glucose metabolism in patients with Hodgkin disease (HD) 
after diagnosis and during chemotherapy treatment. Following 
the administration of first‑line doxorubicin, bleomycin, vinblas-
tine and dacarbazine (ABVD) chemotherapy, 74 HD patients 
underwent 18F‑fluoro‑2‑deoxy‑D‑glucose (18F-FDG) positron 
emission tomography (PET)/computed tomography brain scans, 
both baseline (PET0) and interim (PET2) at the Department of 
Biomedicine and Prevention, University of Rome Tor Vergata 
(Rome, Italy). Fifty-seven patients were further evaluated 
15±6 days after four additional cycles (PET6). Furthermore, 
a control group (CG) of 40 chemotherapy-naïve subjects was 
enrolled. Differences in brain 18F-FDG uptake between the CG, 
PET0, PET2 and PET6 scans were analyzed using statistical 
parametric mapping. Compared with the PET0 and CG scans, 
the PET2 scan demonstrated a higher metabolic activity in 
Brodmann area (BA) 39, and a metabolic reduction in BA 11 
bilaterally and in left BA 32. All of these changes disappeared 
at PET6. The results of the present study indicate that ABVD 
chemotherapy has a limited impact on brain metabolism.
Introduction
Hodgkin disease (HD) is a lymphoproliferative disorder 
with an incidence rate of 2.7-2.8 per 100,000 individuals in 
the UK and the USA in 2013 (1). Doxorubicin, bleomycin, 
vinblastine and dacarbazine (ABVD) chemotherapy (CHT) is 
routinely used in the treatment of HD (2), and is less toxic than 
other chemotherapeutic schemes, such as mechlorethamine, 
vincristine, procarbazine and prednisone (3), and bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine and prednisone regimens (4).
In a recent study investigating the brain glucose metabolism 
in HD patients by means of 2-[18F] fluoro‑2‑deoxy‑D‑glucose 
(18F-FDG) positron emission tomography/computed tomog-
raphy (PET/CT), the hypothesis of brain damage induced by 
ABVD CHT treatment was dismissed (5). However, a strong 
body of evidence demonstrates the coexistence of depression 
and cancer, with a 20-50% prevalence of depression in patients 
exhibiting solid tumors (6). Furthermore, various studies report 
a direct correlation between the rapid progression of cancer 
and severe depression (7). This is consistent with our previous 
study, which supports the hypothesis that metabolic changes 
following CHT may correlate with the transient depressive 
state of cancer patients after diagnosis, followed by an improve-
ment in general and psychological conditions due to a positive 
therapeutic response (5).
The aim of the present study was to investigate the impact 
of ABVD CHT on a larger cohort of HD patients, evaluating 
the brain metabolic changes during the various steps of CHT 
and comparing them with an age-matched control group (CG). 
Furthermore, the possible role of disease severity as a variable 
affecting the brain metabolic changes was investigated in the 
HD patients.
Patients and methods
Patients and CG. From September 2008 to September 2012, 
74 patients (males, 32; females, 42; mean age, 32±11 years) 
with biopsy-diagnosed HD, who were included in a national 
study evaluating the early treatment response to ABVD 
CHT (8), underwent a 18F-FDG PET/CT brain scan in 3D 
mode (9) in association with a whole body staging PET/CT 
study. According to the Ann Arbor staging Criteria (10), 11, 
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35, 11 and 17 patients exhibited stages I, II, III and IV HD, 
respectively.
In accordance with previous studies (11-13), all patients 
underwent the initial PET/CT scan (PET0) within one week of 
HD diagnosis. A second PET/CT scan (PET2) was performed in 
all patients, 15±5 days after the first two ABVD cycles. Written 
informed consent was obtained for a third brain PET/CT 
scan (PET6) from 57 patients (females, 31; males, 26; mean 
age, 31±10 years), which was performed 15±4 days after four 
additional one‑month ABVD cycles, for a total of six cycles.
Forty CHT-naïve subjects (males, 22; females, 18; mean 
age, 36±7 years) undergoing a 18F-FDG PET/CT and found to 
be completely negative for various diseases were enrolled in 
the study and served as the CG (14).
Patients and CG subjects with a history of diabetes, other 
carcinomas, human immunodeficiency virus, neurological, 
psychiatric or mood disorders, surgery, radiation or trauma to 
the brain were excluded from the present study. Furthermore, a 
number of patients treated with agents that could interfere with 
18F‑FDG uptake and distribution in the brain were excluded 
from the present study (16). No patients demonstrated liver or 
renal damage, and no patients were pregnant or breastfeeding. 
Informed consent was obtained from all of the patients, in 
accordance with the Declaration of Helsinki, and the present 
study was approved by the ethics committee of the Hospital of 
Tor Vergata (Rome, Italy).
Treatment strategy. ABVD cycles were repeated every 
28 days. A cycle of treatment consisted of the following on 
day one: doxorubicin, 25 mg/m2; bleomycin, 10,000 units/m2; 
vinblastine, 6 mg/m2; and dacarbazine, 375 mg/m2, which 
were administered intravenously (i.v.). The dose intensity was 
100%, regardless of patient blood count.
PET/CT scanning. The Discovery ST16 PET/CT system 
(GE Medical Systems, Powell, TN, USA) was used to 
assess 18F-FDG distribution in all patients in 3D mode in a 
128x128 matrix. Reconstruction was performed using the 3D 
Table I. Statistical parametric mapping comparisons between 18F-FDG uptake in PET2 and CG.
 Cluster level Voxel level
 -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
 Cluster Corrected Cortical Talairach Maximum Cortical
Comparison extent P‑value lobe coordinates Z score region BA
CG-PET2 1729 0.036 L limbic       -4, 43, 7 4.16 Anterior cingulate cortex 32
   L frontal   -13, 48, 22 3.29 Superior frontal gyrus 11
PET2-CG 546 0.048 R parietal   48, -71, 33 4.78 Angular gyrus 39
For each significant cluster, the number of voxels, the corrected P‑value and the cortical lobe where the voxel is located are reported at the 
cluster level; and the coordinates of the Talairach correlation sites, the Z‑score of the maximum correlation point, and the corresponding cortical 
region and BA are reported at the voxel level. When the maximum correlation is achieved outside of the gray matter, the gray matter (BA) in 
the closest proximity was identified (range, 0‑3 mm). Thresholds of P<0.05, corrected for multiple comparisons using the false discovery rate, 
and P<0.001 uncorrected at voxel level, were implemented for PET2 and CG comparisons.. L, left; R, right; BA, Brodmann's area.
Table II. Statistical parametric mapping comparisons between 18F-FDG uptake in PET0 and PET2.
 Cluster level Voxel level
 -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
 Cluster Corrected Cortical Talairach Maximum Cortical
Comparison extent P‑value lobe coordinates Z score region BA
PET0-PET2 1450 0.017a L limbic       -4, 44, 6 4.21 Anterior cingulate cortex 32
   R frontal     4, 52, -12 3.64 Medial frontal gyrus 11
   L frontal   -8, 48, -26 3.49 Orbital gyrus 11
   L frontal -14, 48, -24 3.47 Superior frontal gyrus 11
PET2-PET0 844 0.042a R parietal   48, -72, 34 4.55 Angular gyrus 39
For each significant cluster, the number of voxels, the corrected P‑value and the cortical lobe where the voxel is located are reported at the 
cluster level; and the coordinates of the Talairach correlation sites, the Z‑score of the maximum correlation point, and the corresponding cortical 
region and BA are reported at the voxel level. When the maximum correlation is achieved outside of the gray matter, the gray matter (BA) 
in the closest proximity was identified (range, 0‑3 mm). Thresholds of P<0.05, corrected for multiple comparisons using the false discovery 
rate, and P<0.001 uncorrected at voxel level, were implemented for PET0‑PET2 and PET2‑PET0 comparisons. aP<0.05 corrected for multiple 
comparisons at cluster level. 18F‑FDG, 2‑[18F] fluoro‑2‑deoxy‑D‑glucose; PET, positron emission tomography; CT, computed tomography; 
PET0, brain 18F-FDG PET/CT scan within one week of Hodgkin disease diagnosis; PET2, brain 18F‑FDG PET/CT scan 15±5 days after the first 
two adriamycin, bleomycin, vinblastine and dacarbazine cycles; CG, control group; BA, Brodmann area; L, left; R, right. 
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reconstruction method of ordered subsets expectation maximi-
zation with 21 subsets and four iterations. The system combines 
a high-speed ultra 16-detector-row (912 detectors/row) CT unit 
and a PET scanner with 10,080 bismuth germanate crystals in 
24 rings. The axial full width half maximum (FWHM) was 
1 cm (3D mode radius, 5.2 mm) and the axial field‑of‑view was 
157 mm. All patients and CG subjects fasted for a minimum of 
5 h prior to i.v. 18F-FDG injection to produce a serum glucose 
level of ≤120 mg/ml. All of the subjects in the present study were 
intravenously injected with 3 MBq/kg (range, 210-350 MBq) 
18F-FDG and hydrated with 500 ml i.v. saline NaCl 0.9%.
18F-FDG was administered to each patient in a dedicated, 
dark room. All of the patients were required to remain in a 
resting condition with closed eyes prior to the PET/CT scan. 
Following a 45 min rest period, the brain PET/CT scan was 
performed by placing the patient's head in a support. A 
low-amperage CT scan of the head was performed for attenu-
ation correction (40 mA; 120 Kv), prior to obtaining the PET 
image. The duration of the brain PET image set acquisition 
was 15 min in all of the patients. All brain PET scans were 
performed prior to the whole body PET scan, consisting 
of a low-amperage CT scan for attenuation correction of 
PET images (80 mA; 140 kV; field of view ~450±5 mm; 
CT slice thickness, 3.75 mm). The CT Dose Index for ldCT 
was 4.0175 (±0.84) mGy and the dose-length product was 
473.296 (±161.09) mGy-cm. After non-enhanced CT, total-
body PET examination in the caudocranial direction from 
the upper thighs to the vertex was performed (every bed of 
the PET acquisition lasted 3.5 min). Reconstruction was 
performed using the 3-dimensional reconstruction method 
Figure 1. Brain 2‑[18F] fluoro‑2‑deoxy‑D‑glucose positron emission tomography (PET)/computed tomography scan (A) within one week of Hodgkin disease 
diagnosis (PET0) and (B) 15±5 days after the first two adriamycin, bleomycin, vinblastine and dacarbazine cycles (PET2).
  B  A
Figure 2. (A) Significant cortical hypometabolism in positron emission tomography (PET)2 when compared with the PET0 group. Threshold of P<0.05, cor-
rected for multiple comparisons with false discovery rate at voxel level. (B) High 2‑[18F] fluoro‑2‑deoxy‑D‑glucose uptake in the right superior parietal lobule 
in PET2 compared with PET0. Threshold of P<0.001, not corrected for multiple comparisons at voxel level. Coordinate and regional details are presented in 
Table I. PET0, brain 2‑[18F] fluoro‑2‑deoxy‑D‑glucose (18F-FDG) PET/computed tomography (CT) scan within one week of Hodgkin disease diagnosis; PET2, 
brain 18F‑FDG PET/CT scan 15±5 days after the first two adriamycin, bleomycin, vinblastine and dacarbazine cycles.
  A   B
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of ordered‑subsets expectation maximization (OSEM) with 
30 subsets and two iterations.
Statistical analysis. Differences in brain 18F-FDG uptake were 
analyzed using statistical parametric mapping (SPM2; Wellcome 
Department of Cognitive Neurology, London, UK) implemented 
in MATLAB 6.5 (Mathworks, Inc., Natick, MA, USA). PET 
data were subjected to linear (affine) and non‑linear spatial 
normalization into the Montreal Neurological Institute space. 
The spatially normalized images were smoothed with a 12-mm 
isotropic Gaussian filter to blur for individual variations in gyral 
anatomy and to increase the signal-to-noise ratio. Images were 
globally normalized to 50 ml/100 ml/min using proportional 
scaling to remove the confounding effects of changes in the 
global cerebral glucose consumption, with a masking threshold 
of 0.8. The resulting statistical parametric maps, SPM{t}, were 
transformed into normal distribution (SPM{z}) units. SPM coor-
dinates were corrected to match the Talairach coordinates, 
according to the method implemented by Brett (http://imaging.
mrc-cbu.cam.ac.uk/imaging/MniTalairach). Subsequently, 
Brodmann areas (BAs) were identified at a range of 0 to 3 mm 
from the corrected Talairach coordinates of the SPM output 
isocenters, using Talairach Client software (http://www.talai-
rach.org/client.html). Consistent with Bennett et al (15), the 
threshold of the SPM{t} maps was P<0.05, corrected for multiple 
comparisons using false discovery rate (FDR) at voxel level, and 
P<0.01, corrected for multiple comparisons using FDR at cluster 
level. Due to the explorative nature of the present study, when 
statistically significant differences were not identified at such 
conservative thresholds, a threshold of P<0.001 uncorrected at 
voxel level was set. Only those clusters containing >125 contig-
uous voxels (i.e. >5x5x5 voxels or >11x11x11 mm) were accepted 
as significant, due to the partial volume effect caused by the 
poor spatial resolution of the PET camera (~2 x FWHM). The 
voxel‑based analyses were performed using a modality‑adjusted 
paired t-test (two conditions, one scan/condition) and the 
following comparisons were assessed: i) PET0 vs. PET2 and 
vice versa; ii) PET0 vs. PET6 and vice versa, CG vs. PET0, 
CG vs. PET2, CG vs. PET6 and vice versa. Age and gender were 
used as nuisance variables in all analyses and disease staging 
was added as nuisance variable in the CG vs. PET2 comparison. 
Two-way analysis of variance was used in demographic data 
analyses to assess differences in gender and age. P≤0.05 was 
considered to indicate a statistically significant difference and, 
thus, a valid hypothesis.
Results
No significant differences were identified in age and gender 
between HD and CG subjects. However, when PET2 data 
were subtracted from PET0 and CG data, a significant 
hypometabolic area including a portion of the orbitofrontal 
cortex (OFC) bilaterally (BA11) and left anterior cingulate 
cortex (ACC; BA32; Table I) was identified. When compared 
with PET0 (Table II; Fig. 1) and CG (Fig. 2) scans, PET2 
scans demonstrated a significantly higher 18F-FDG uptake 
distribution in the right angular gyrus (BA39; Table I). No 
significant differences were identified when subtracting 
PET6 from PET0 and CG scans and vice versa. Furthermore, 
the 18F-FDG uptake distribution changes identified at PET2 
disappeared at PET6, and no significant changes were iden-
tified between PET6 and PET2, PET0 or CG at any of the 
explored statistical thresholds.
When using the stage of the disease as the nuisance 
variable, no significant differences were identified in the 
comparisons between PET0, PET2 or PET6 data and CG data.
Discussion
The predominant finding of the present study was a signifi-
cant hypometabolism in OFC bilaterally (BA11) and in the 
left ACC (BA32), and an increased glucose consumption in 
the right parietal cortex, in HD patients following the first 
two CHT cycles. These changes disappeared at the termina-
tion of the therapy, six months after diagnosis.
The present study confirms, in a larger series of patients, 
the results of a previous report and, thus, reinforces its reli-
ability (5). Furthermore, the present study compared the 
metabolic status of HD patients with that of a CG, improving 
the design and the overall statistical power of the study.
Possible CHT-induced damage in BAs 11 and 32 may be 
important in the reduced brain glucose metabolism in these areas 
following the first two cycles of CHT. Although chemotherapeutic 
agents typically have restricted direct access to brain tissue due to 
the blood-brain barrier, animal studies indicate that even chemo-
therapeutic agents not known to readily cross the blood-brain 
barrier (for example, doxorubicin used in the present study) are 
associated with reduced neurogenesis (16,17). In contrast to the 
previous study using significantly fewer patients (5), the current 
study did not demonstrate any differences between the PET6 and 
PET0 18F‑FDG distributions. Furthermore, no significant differ-
ences were detected between the CG scan and the brain PET 
scan at the termination of therapy (PET6).
In the case of CHT-induced brain damage, a diffuse 
cortical and sub-cortical reduction in brain glucose consump-
tion at PET2, followed by a further reduction after four 
more CHT cycles, would be expected (18). The present study 
demonstrated that the metabolic changes that occurred during 
the disease course and the restoration of normal metabolism in 
the ACC and PFC at the termination of therapy do not appear 
to be associated with the total dose of CHT administered.
These findings, in particular those derived from the compar-
ison with CG subjects, are in disagreement with a previously 
published study exploring functional changes in the brains of 
CHT-treated patients (19), and dispute claims that ABVD CHT 
may induce permanent brain damage (19). A previous study eval-
uating the impact of CHT in female breast cancer patients using 
magnetic resonance imaging indicated that CHT may cause 
permanent disruption in the networks of various brain regions (in 
particular in the hippocampus), thus, directly affecting cerebral 
function in these areas (20). These disruptions may be associated 
with specific activation/deactivation patterns in different areas 
of the cerebral cortical during tasks and at rest (for example, the 
frontal cortex), as reported by Silverman et al (21).
However, a recent study outlined that, during neuropsycho-
logical testing, patients who were treated with CHT performed 
worse than non-cancer control participants. However, 
CHT-treated patients improved upon their own pre-CHT base-
line and performed better than patients treated without CHT, 
indicating that the majority of long‑term cognitive deficits 
ONCOLOGY LETTERS  9:  685-690,  2015 689
associated with CHT-treated breast cancer patients are gener-
ally small in magnitude (22).
The lack of a permanent brain metabolic dysfunction identi-
fied in the present study may be due to the different types of CHT 
used and the different periods of examination during the disease 
course (~5-10 years in the cited studies; in the acute phase of 
CHT in the present case) (20,21). ABVD is considered to be less 
toxic when compared with other CHT schemes (3,4); however, 
further studies are required to investigate a possible delayed 
effect of ABVD CHT on brain function and metabolism.
Various changes in the structure and function of the OFC 
and ACC have been described in different psychiatric condi-
tions. In particular, structural neuroimaging studies have 
observed a reduction in the gray matter volume of ACC, and 
left and right OFC among patients with major depressive disor-
ders (23,24). During traumatic exposure in patients exhibiting 
post‑traumatic stress disorder (PTSD), a significant decrease 
in cerebral blood flow (CBF) has been identified in the ACC 
and OFC, and a significant increase in CBF has been identified 
in right parietal regions (25-28). The temporary reduced brain 
glucose metabolism in the OFC and ACC, and the increased 
metabolism in the right parietal cortex may be explained by 
the presence of an acute anxiety status in the present patients. 
This hypothesis is consistent with the development of depressive 
symptoms in cancer patients caused by the stress of diagnosis 
with a life-threatening disease (29). Additionally, cancer diag-
nosis and treatment are accompanied by a number of acute and 
chronic stressors that can impact the patient quality of life (29).
In the present study, all patients examined by PET6 were 
disease-free for a minimum of 12 months and presented a 
negative whole body PET scan after two ABVD cycles. 
Thus, treatment with two cycles of ABVD is associated with 
a high disease-free survival rate in HD patients (10-12). It 
is possible that the good prognosis in the present series of 
patients resulted in the disappearance of psychiatric symp-
toms (time period, 6-12 months), as previously reported in 
patients affected by cancer (30). However, various functional 
imaging analyses of patients exhibiting mood disorders 
identified an increased or a decreased CBF or metabolism 
in BA 11 and 32, despite the majority of patients exhibiting 
increased CBF or metabolism at rest (28,31).
The largest regional metabolic differences were identified 
in the comparison of PET2 with PET0 and CG (Tables I and 
II). At this point of the disease course (15±5 days after the first 
two ABVD cycles), a high level of anxiety would be expected, 
due to: (i) The recent diagnosis (within two months) and (ii) the 
uncertainty of the therapeutic outcome (12,13). This acute 
anxiety may impact brain metabolism and blood flow. Although 
the patient may remain in a state of anxiety associated with the 
possibility of disease recurrence prior to PET6 examination (13), 
no significant differences in brain metabolism were identified 
when comparing PET6 with PET0 and CG scans. This supports 
the hypothesis of an acute and transient psychiatric condition 
that affects patients early during the disease course.
The severity of the disease appears to be associated with 
metabolic changes observed in the brains of HD patients. 
When the disease stage was used as a nuisance variable in the 
comparison of PET2 and CG scans, no significant difference 
was identified, possibly due to the patient's perception of a 
more advanced disease stage as a worse prognostic factor. This 
is supported by a study performed on a large cohort of patients 
exhibiting different types of cancer; the presence of metastases 
was associated with an increased number of anxiety symptoms 
and early disease stage was associated with fewer depressive 
symptoms (7,32). However, it has been demonstrated that the 
distribution of 18F-FDG uptake in healthy tissues is associated 
with disease progression in HD (33). Furthermore, various 
studies have demonstrated that the tumor or treatment-induced 
inflammation can promote the production of peripheral proin-
flammatory cytokines. Proinflammatory cytokines activate 
central nervous system pathways that may induce behavioral 
and affective symptoms, such as a depressed mood, fatigue, 
anorexia, impaired concentration, sleep disturbance, enhanced 
pain sensitivity and reduced activity (29,34-36). Therefore, 
subsequent studies should include longitudinal neuropsycho-
logical, psychiatric and laboratory assessments.
In contrast to previous reports (5), the present study demon-
strated no significant metabolic changes in BA 10 (prefrontal 
cortex) in HD patients receiving ABVD CHT. This discrep-
ancy may explained by the larger number of patients examined 
in the present study, introducing a higher inter-individual vari-
ability and, thus, no significant differences. The previous (5) 
and present cluster of voxels resulting from the group 
comparisons were almost superimposable and the reported 
results predominantly differ in the coordinates of the isocen-
ters determined by SPM. However, in respect to its functional 
role in major depression and/or PTSD, the prefrontal cortex 
and orbito‑frontal cortex voxel clusters superimpose well (28). 
Furthermore, stress symptoms in cancer patients have been 
previously described (30,37,38), and several studies describe 
diagnosis-associated psychological trauma in cancer patients 
and survivors, for example acute and chronic PTSD (39,40).
As the design of the present study did not consider the 
co-occurrence of HD and other psychiatric disorders, the possible 
occurrence of an acute and transient anxiety status is only specu-
lative. The present study achieved its aim of evaluating alterations 
in brain metabolism in HD patients during various stages of 
ABVD CHT treatment and compared with a CG; however, 
the impact of the psychological status of the patient was only 
considered post hoc. Thus, the lack of a neuropsychological or 
psychiatric evaluation following disease diagnosis and during 
treatment is an evident limitation of the present study.
Another possible limitation of the present study is the 
use of a CG of subjects with a negative brain PET scan, 
as opposed to a group of healthy volunteers. However, it is 
important to note that the CG was specifically set up for 
the present study, and identical protocol and scanners were 
used for patients and controls. This is important in neuro-
imaging studies where the number of potential confounding 
variables must be minimized. The use of a CG comprising 
of a sample of individuals with a negative PET is common, 
due to the high costs associated with obtaining a cohort of 
volunteers. Furthermore, the stringent exclusion criteria were 
the same as those applied in previous investigations (41,42). 
In addition, using a CG comprised of neurologically healthy 
subjects undergoing PET scans for other reasons prevents 
healthy individuals being exposed to radiations and makes 
the protocol feasible for the majority of PET centers, as it 
reduces the costs and efforts required to build up CGs 
comprised of healthy subjects (43).
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In conclusion, brain metabolic changes in a large cohort 
of HD patients during the initial phases of CHT are transient 
and may be due to an acute anxiety state following disease 
diagnosis and treatment outcome uncertainty. Further studies 
integrating this data with neuropsychological, psychiatric and 
laboratory assessments are necessary to confirm the hypoth-
eses of the present study.
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